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A B S T R A C T
Background: In developing countries, Epstein–Barr virus (EBV) infection is mostly asymptomatic in early
childhood. EBV persistence may lead to different malignancies, such as B cell derived lymphomas. In
Argentina, most children are seropositive at three years and an increased association between EBV and
lymphoma was proved in children under 10 years old by our group.
Objective: Our aim was to characterize EBV infection at the site of entry and reactivation of viral infection
—the tonsils— in order to better understand the mechanism of viral persistence in pediatric patients.
Methods: A cohort of 54 patients was described. We assessed specific antibodies profiles in sera; viral
proteins presence by IHC on FFPE samples and EBV type from fresh tissue.
Results: EBV type 1 was prevalent, mostly in the youngest patients. Asymptomatic primary infected
patients presented higher viral loads and Latency 0/I or II patterns, whereas the Latency III pattern was
observed mostly in healthy carriers. There were no differences between groups in the expression of viral
lytic antigens. This study discloses new features in patients undergoing primary infection from a
developing population. Low viral inoculum and restricted viral antigen expression may be responsible for
the lack of symptoms in children from our country.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Epstein–Barr virus (EBV) is a member of the Gamma
Herpesvirus family, which infects almost 90% of the people
worldwide. Its primary target is human B lymphocytes, where it
establishes a lifelong persistent infection, mostly asymptomatic
(Hatton et al., 2014).
The mechanism of the EBV persistence, like all of the
herpesvirus family, consists of two phases: the latent cycle, in
which viral antigen expression is restricted to a minimum in order
to avoid immune surveillance; and the lytic cycle, which creates
new infectious virions that are spread by the saliva (Szymula et al.,
2018).
The greater disease burden produced by EBV has been highly
associated with several types of epithelial cell carcinoma, such as* Corresponding author.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).nasopharyngeal and gastric carcinoma, and B cell lymphoma,
including Burkitt lymphoma, posttransplant lymphoproliferative
disorder, and Hodgkin and non-Hodgkin lymphoma (Szymula
et al., 2018). In this regard, EBV-associated neoplasias are related to
the expression of different latency programs(Thorley-Lawson et al.,
2008) that alternatively express viral proteins with oncogenic
properties(Young and Murray, 2003; Young et al., 2016).
Four latency stages were described on the basis of differential
EBV gene antigen expression: Latency 0 (L0), where no viral
antigens or only EBERs transcripts are expressed; Latency I (LI),
which involves the expression of EBERs and EBNA1; Latency II (LII),
when B cells express EBERs, EBNA1 and both transmembrane viral
proteins LMP1 and LMP2A/B; and, finally, Latency III (LIII) where all
viral antigens are expressed, including EBNA2 and EBNA3s
(Kuppers, 2003). Alternatively, Latency IIb was also suggested,
when B cells express EBNA2 without latent membrane proteins
(Kurth et al., 2003).
The study of the primary infection has proved to be difficult, not
only because of the long incubation period before symptom
appearance, but also because this period is nearly impossible tociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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primary infection studies are based in cases of Infectious
Mononucleosis (IM) in adolescents or adult patients. The occur-
rence of IM is significantly higher in developed countries, and is a
consequence of the delay of the primary infection until adoles-
cence or young adulthood. IM elicits a strong response of the
immune system, characterized for massive CD8+ T cells expansion,
mostly EBV-specific (Abbott et al., 2017), and also displays an
elevated viral load, detectable in saliva as well as in peripheral
blood (Balfour et al., 2015). Moreover, during the early stages of
primary infection, EBV shows the complete antigen expression, LIII
program(Thorley-Lawson, 2015), which is sequentially silenced,
either through the germinal center(GC) reaction or by the
generation of a GC-like environment (Shannon-Lowe et al.,
2017) once the persistence is accomplished.
Those difficulties are also present in children, mostly because of
the lack of symptoms. A recent study, performed with samples
from pediatric patients undergoing tonsillectomy, was published
(Jud et al., 2017), but it was carried out in a highly developed
country and was focused only on the immune response. On the
other hand, although there are a few studies of primary infected
children from developing countries, such as the Jayasooriya et al.
and Piriou et al. reports, that aim to determine the characteristics
of primary infection in a cohort of African children (Jayasooriya
et al., 2015; Piriou et al., 2012), or the Slyker et al. study (Slyker
et al., 2013), which focused on HIV infected children; these results
were restricted to peripheral blood samples, which do not
accurately reflect the underlying mechanisms of what happens
in the tonsils, the site of infection. Thus, deep characterization of
primary EBV infection in developing countries like Argentina, in
which viral infection occurs almost exclusively in the first years of
life, and where the incidence of EBV-associated lymphomas in
children younger than 10 years old is higher (Chabay, Preciado,
2013), is needed.
Therefore, in the light of these considerations, our aim was to
characterize and compare EBV infection in tonsil tissue from
children undergoing either primary infection or viral reactivation
and healthy carriers, as a way to better understand viral infection
stages.
Results
Serological status and viral load
In order to establish the EBV serological status, the presence of
VCA-IgM, VCA-IgG, Early Antigen (EA)- IgG and EBNA1-IgG was
determined in study participants’ sera according to previous
reports (Klutts et al., 2009). Fifty-four samples were analyzed by
this approach, the median age of this group being 5 years old
(ranging from 1 to 15) with female predominance (30/54, 55.5%).
Four groups were defined based on these results: asymptomaticTable 1
Differentiation of four groups based on their EBV serological profile.
Group N Median Age (range) VCA-IgM VCA-IgG 1/10 VCA-IgG 
PI 18 4 (2–12) ++ +/ +/ 
HC 25 6 (2–15) - + + 
R 7 5(2–8) +/ + +/ 
NI 4 4(1–7) - - - 
Total 54 5 (1–15) 
*Statistical difference (p = 0,0051). PI: asymptomatic primary infected children, HC: Heal
viral load (copies/ug DNA). N: patients per group. VCA-IgM: IgM Ab against the viral c
dilutions used in the VCA-IgG titration. EA-IgG: early antigen directed IgG (sera dilution u
+: positive. +/: either positive or negative. : negative.primary infected patients (PI) identified as VCA-IgM+/VCA-IgG-/+/
EA-IgG-/ EBNAI-IgG-; healthy carriers (HC) identified as VCA-IgM-/
VCA-IgG+/EA-IgG-/EBNAI-IgG+, patients undergoing viral reactiva-
tion (R) identified as VCA-IgM+/-/VCA-IgG+/EA-IgG+/EBNAI-IgG+
and non-infected patients (NI) identified as VCA-IgM-/VCA-IgG-/
EA-IgG-/EBNAI-IgG-. Among the studied group 18 turned to be PI,
25 HC, 7 R and 4 NI cases, the median age being 6 years old for HC, 5
years old for R and 4 years old for both PI and NI patients (Table 1).
Even though no statistical differences among ages were observed
between groups, HC median age was slightly higher. All patients’
data is summarized in Table 2.
Viral load at the tonsils was unexpectedly low in all groups, the
global mean being 988 viral copies/ug of DNA. When the four
groups were analyzed separately, the mean viral load was 4854
viral copies/ug of DNA in API, 339 viral copies/ug of DNA in HC and
345 viral copies/ug of DNA in R group. As expected, APIs mean viral
load at the tonsils was statistically higher than in the rest of the
groups (p = 0.0051, Kruskal–Wallis test).
Latency and lytic viral proteins expression
The presence of EBV latent proteins LMP1, LMP2A and EBNA2,
along with the lytic cycle protein BMF1 was assessed by IHC (Figure
1A–E). In addition, EBERs transcripts expression was evaluated by
ISH. Latency patterns were identified as follows: L0, cases without
viral antigen expression; L0/LI, cases with EBERs expression; LII,
EBERs together with LMP1 and/or LMP2A; LIII, LII proteins together
with EBNA2 expression; LIIb, LI plus EBNA2 expression, without
LMPs.
Given the lack of anti-EBNA1 antibodies for FFPE tissue that
restrain us from defining L0 accurately, we decided to grouped L0
patients within the LI category in the analysis. Also, we grouped
LIIb with LIII cases because the first pattern is considered to be an
immediately previous stage of the LIII pattern (Kurth et al., 2003).
On the other hand, cells undergoing the viral lytic cycle (LC) were
defined by nuclear antigen BMRF1 expression.
A total of 29 patients displayed L0/LI pattern, 12 LII and 9 LIIb/
LIII, whereas only 8 children presented cells with lytic cycle protein
BMRF1 expression along with cells expressing latent antigens.
When divided in groups, 10 PI,15 HC and 4 R children expressed L0/
LI antigens; 8 PI, 2 HC, and 2 R patients showed LII, while LIIb/LIII
profile was identified in 8 HC and 1 R children. Unexpectedly, 6 out
of the 8 cases with presence of LC antigens turned out to be HC
while only 2 were R patients. These results are summarized in
Table 3.
When LC and latency patterns were analyzed altogether, we
observed that BMRF1 was expressed along with LI antigens in 2 HC
and 1 R children, with LII antigens in 3 HC and none R patients, and
with LIII antigens in 2 HC and 1 R patients. Non statistically
differences were found in LC antigen expression among the three
latencies in LC antigen expression (p > 0.05, X2 test).1/40 VCA-IgG 1/320 EA-IgG EBNA1-IgG Mean VL* (copies/ug DNA)
(SEM)
+/ - - 4854(1788)
+/ - + 339(101)
+/ + + 345(56)
- - - -
988(492)
thy carriers, R: children undergoing viral reactivation, NI: non-infected children. VL:
apsid. VCA-IgG: IgG Ab against viral capsid. 1/10; 1/40 and 1/320 were the serum
sed: 1/10) EBNA1-IgG: EBNA1 directed IgG (sera dilution 1/10). ++: intense positivity.
Table 2
All patient characteristics.
Patient Age Sex Viral Load EBV type LMP1 EBNA2 EBERs Latency BMRF1
PI
3S 4 F 0 N/D - - + LI -
4S 12 M 1840 1/2 + - - LII -
5S 3 M 143000 1 - - + LI -
10S 10 F 0 N/D - - + LI -
14S 10 F 0 N/D - - + LI -
15S 6 F 0 N/D + - + LII -
26S 5 F 41000 1 + - + LII -
28S 2 M 8410 2 - - + LI -
32S 8 M 0 N/D + - + LII -
33S 4 M 1280 1 - - - L0 -
37S 2 M 3860 1 - - + LI -
40S 3 M 1450 2 + - + LII -
41S 3 M 120 1 + - - LII -
42S 5 F 0 N/D + - + LII -
52S 3 M 15200 2 - - + LI -
53S 4 F 14000 1 - - + LI -
54S 11 F 540 1 - - + LI -
60S 5 F 1840 1 + - + LII -
HC
11S 10 F 4260 2 - - + LI +
20S 7 M 100 1 - - + LI -
25S 9 F 0 N/D + - - LII +
29S 8 F 140 1 - - - L0 -
31S 2 M 310 1 - - + LI -
35S 9 F 0 N/D - - - L0 -
34S 4 M 240 N/A - - + LI -
38S 6 F 28500 1 - - + LI -
39S 7 F 460 2 - - + LI -
44S 2 F 22000 1 - - + LI -
47S 4 M 0 N/D - + + LIIb -
56S 6 F 0 N/D - + + LIIb -
57S 12 F 950 N/A + + + LIII -
58S 8 F 0 N/D - - - L0 -
59S 15 F 430 2 + - + LI +
61S 8 M 0 N/D - - - L0 +
63S 3 F 0 N/D + - + LII +
64S 5 F 100 1 - - + LI -
65S 8 M 0 N/D - + + LIII +
66S 2 M 0 N/D - + + LIIb -
71S 4 F 570 2 - - - L0 -
72S 4 M 0 N/D + + + LIII -
73S 6 M 2880 1 - + + LIII +
74S 3 F 0 N/D - + + LIII -
77S 10 F 0 N/D - - - L0 -
R
13S 5 M 290 1 - - + LI -
19S 8 M 400 1 - - + LI -
27S 2 M 1250 2 - + + LIII +
51S 2 M 560 1 - - - L0 -
55S 8 M 220 1 + - + LII -
62S 5 F 0 N/D + - + LII -
69S 3 F 940 2 - - + LI +
NI
30S 7 M 0 - - - - / -
46S 1 F 0 - - - - / -
50S 1 F 0 - - - - / -
68S 11 F 0 - - - - / -
N/D: Not detectable: EBV typing assay was negative even after performing the semi-nested PCR.
N/A: DNA not available for the test.
Presence of viral antigen was assessed in the complete tissue slide and expressed as positive or negative
L0: Latency 0 profile; LI: Latency I profile; LII: Latency II profile; LIIb: Latency IIb profile; LIII: Latency III profile.
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and EBNA2 stained cells were located in the interfollicular zone
(IF), except a few cases, where EBERs positive staining was
detected in germinal center (GC).
Surprisingly, neither LIII pattern nor cells expressing BMRF1
antigen were observed in children undergoing asymptomatic
primary infection. In contrast, we found that full latency antigen
repertory (LIII) was proven almost exclusively in HC (p = 0.0374,Fisher exact test). Viral load showed no differences when
compared among the four latencies patterns (p > 0.05, Kruskal–
Wallis test), but when LI was compared with LII and LIII grouped
together, viral load was significantly higher in LI (p = 0.028, Mann–
Whitney test). In addition, there were no differences in mean age
between the four latencies patterns (p > 0.05, Kruskal–Wallis test),
which is explained by the lack of age differences between groups of
patients.
Figure 1. In Situ Hybridization and Immunohistochemistry on FFPE tonsils. (A) EBERs transcripts expressed in cells’ nuclei. (B) LMP1 expressed on cells’ membrane and
cytoplasm. (C) LMP2A expressed in the membrane of the cells. (D) EBNA2 nuclear expression. (E) BMRF1 nuclear expression. Digital images were obtained with an
AxioCamErc 5 s (Zeiss) camera and acquired using Digital Axio Vision Rel. 4.8 image acquisition software. Original magnification 400, insets 1000.
Table 3
Viral antigen expression.
Group L0/L I L II LIIb/L III* LC
API 10/18 (55,6) 8/18 (44,4) 0/18 (0) 0/18 (0)
HC 15/25 (60) 2/25 (8) 8/25 (32) 6/25 (24)
R 4/7 (57) 2/7 (29) 1/7 (14) 2/7 (29)
Total 29/50 (58) 12/50 (24) 9/50 (18) 8/50 (16)
*Statistical difference(p = 0,036). Latency I, II, IIb and III patterns and Lytic Cycle
antigen expression were defined in each subgroup of patients. The percentages of
cases expressing the viral antigens are shown between the parentheses.
Figure 2. EBV typing by one round PCR from tonsils samples. PI: Asymptomatic
primary infected children, HC: Healthy carriers, R: Patients undergoing viral
reactivation T1: EBV type 1 positive control (B95.8 cell line) T2: EBV type 2 positive
control (P3HR1 cell line) C-: negative control (without DNA input) MWM:
molecular weight marker
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EBV is divided in two types, recognized as EBV-1 and EBV-2,
which have been distinguished based upon genetic differences in
the EBNAs. For this purpose, DNA samples from patients with viral
load above the detection limit were selected. Out of 33 patients
that met this condition, we had available DNA to be tested from 31:
12 PI,13 HC and 6 R children. Specific PCR product was proven in 27
patients (age range 2–15 years) in a first round PCR (Figure 2).
Nineteen were positive for EBV-1, 7 for EBV-2, and 1 patient was
co- infected. When analyzed by serological status, 8 PI patients
were positive for EBV-1 and the remaining one was co-infected; in
the HC group, 8 were positive for EBV-1 and 5 for EBV-2, and, in the
R patients, 3 were positives for EBV-1 and 2 for EBV-2, there were
no statistical differences in viral subtypes between groups (p >
0.05, X2 test). To further analyze the remaining 4 patients, we
performed a semi-nested PCR and found that the 3 PI children were
infected with EBV-2 and the R child was infected with EBV-1 (data
not shown).
Given that previous reports (Coleman et al., 2017; Coleman
et al., 2018) proposed that the EBV-2 could infect T cells in younger
patients, we evaluated the results classifying the patients in two
groups according to their ages: those younger than 10 years old and
those which were 10 years old or older. Of 26 patients that belong
to the first group,19 were EBV-1 and 7 EBV-2. Regarding the 5 older
children, 1 was positive for EBV-1, 3 for EBV-2 and 1 was co-
infected. Consistent with these results, EBV1 is statisticallydistributed among younger children (p = 0.0466, Fisher exact
test). There were no statistical differences between patients
infected with EBV-1 or EBV-2 neither in mean viral load, mean
age (P > 0.05, Mann–Whitney) nor latency profiles (P > 0.05, Fisher
exact test).
Discussion
EBV primary infection was mostly characterized in adult
patients with infectious mononucleosis, whereas little is known
about viral load, latent and lytic gene expression at the site of viral
entry and reactivation in children undergoing primary infection
(Vistarop et al., 2016). Our approach is the first that identifies
differential stages of asymptomatic viral infection in a significantly
large cohort of pediatric patients outside Africa. In Argentina,
children acquire the infection in the first few years of life, and
seroconversion is often seen by ages 3–4 years, whereas infection
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and Preciado, 2013). In this cohort, EBV serology was performed in
order to differentiate patients undergoing EBV asymptomatic
primary infection (PI), healthy carriers (HC) and children
undergoing reactivation of viral infection(R). As far as we know,
EBV characterization in this last group was never performed.
Surprisingly, in our series, even though a lower age for children
with primary infection was expected, no differences in age among
the four groups were demonstrated. Also, the PI, HC and R groups
displayed a median age of 4, 6 and 5 years respectively, showing
the fact that children, in our population, are infected at a very early
age, in line with previous results in children from Africa
(Jayasooriya et al., 2015; Piriou et al., 2012). This fact might reflect
a combination of age of infection and developing environment,
given than in developed populations, the age of primary infection
increases (Balfour et al., 2015). Additionally, the low age difference
between children undergoing viral reactivation and PI or HC may
point out that this event occurs in a relatively short period after the
primary infection.
Previously, a higher EBV viral load in plasma among pediatric
patients with recent asymptomatic infection has been reported, as
well as among patients undergoing IM (Jud et al., 2017), and even in
some cases including young adults with no IM symptoms. In
contrast, our study revealed that, even though viral load was
assessed in tonsils, and it was statistically higher between PI
children, all of the infected patients presented lower viral load. These
results pointoutthat low viral load observedin thiswork atthe site of
viralentryandreactivation, the tonsils,may beresponsible,at least in
part, for asymptomatic infection characteristics. Furthermore, our
findings are similar to those of Seishima et al. (2017), in which the
authors used fresh tissue samples from adults and pediatric patients
to determine viral load, that was lower that the viral load of our
cohort (median 57 copies/ug of DNA).
Regarding the expression of viral proteins, numerous studies
reported that, in post-transplanted and IM patients’ tonsils, most of
the latency antigens were found in the extrafollicular zones with
exception of a few cases that expressed EBERs transcripts in the GC
(Kurth et al., 2003; Meru et al., 2001; Niedobitek et al., 1997;
Roughan et al., 2010). In addition, the frequency of EBV-infected GC
B cells in normal persistently infected individuals is very low
(Roughan et al., 2010). In contrast, Barros et al described that
around 50% of cells were infected by EBV in 16 patients with IM
(Barros et al., 2019). In our series, only a few cells located at the GC
were infected by EBV as well, without differences among the three
groups.
EBV latent protein expression in tonsils so far rendered
conflicting results, since in some studies EBV serological status
is unknown. LMP1 expression in tonsillar B cells was previously
described in 20 EBV infected patients randomly chosen, along with
EBNA2 presence in a few cases (Hudnall et al., 2005). In contrast,
EBNA2 expression was not described in 6 patients with tonsillec-
tomy (Babcock and Thorley-Lawson, 2000). In our group, an
unexpected prevalence of LI and LII was demonstrated in PI
patients, which differ with most previous findings in adult patients
undergoing primary infection, where the virus displayed the full
LIII pattern (Kurth et al., 2000; Thorley-Lawson and Gross, 2004). It
was demonstrated that six cases displayed an alternative latency
pattern that expressed EBNA2 without LMP1 (Kurth et al., 2003).
This LIIb form of latency was proposed as the first latency pattern
observed following primary infection of B cells, characterized by
EBNA2+/LMP1- gene expression phenotype. Recent work has
demonstrated that this latent gene expression state is observed
after EBV infection for approximately two weeks before transition-
ing to the full LIII state in LCLs (Price and Luftig, 2015).
Furthermore, we only found LIII in HC, where EBV already
established a persistent infection, questioning the previouslyreported L0 pattern of infection in those patients (Thorley-Lawson
et al., 2013).The presence of LIIb and LIII pattern in R and HC, along
with the expression of lytic antigens in both groups, may be due to
newly infected tonsillar B cells by recently produced viral particles
at this histological region. The lack of full latent gene expression in
PI children may also explain the asymptomatic infection in this
group, reinforced by the absence of lytic antigen expression, as
previously observed (Niedobitek et al., 2000). This fact might
denote that LC does not play a central role in primary infection
(Coleman et al., 2017).
A high viral load in blood and in the oral cavity was described in
adults with infectious mononucleosis (Abbott et al., 2017)
associated with the LIII pattern, that includes EBERs transcripts,
along with LMP1 and EBNA2 latent proteins (Young and Rickinson,
2004). However, when mean viral load was compared between the
L0/LI cases and LII/LIII ones, we found that children with higher
viral load were the ones that expressed the L0/LI pattern. This was
not unexpected, given the fact that most of LI expressing cases
were PI children. These findings reinforce our hypothesis that
asymptomatic primary infection in children presents differences
with IM in adults and adolescents.
It was previously reported, in a cohort of patients from a
developing country, that the coexistence of the two EBV types (1
and 2) is possible in those infants and, additionally, EBV type 2 was
associated with younger children, in particular on T cells, while
type 1 prevailed in B lymphocytes in older children from Kenya
(Coleman et al., 2018). In our territory, the circulation of EBV type 2
is lower with respect to EBV type 1, as previously described by our
group (Chabay and Preciado, 2013). However, in contrast to
previous reports in Kenya, EBV type 1 was prevalent in younger
patients, whereas type 2 was associated with the older ones. In
addition, even though a statistical difference was not proven, EBV-
1 prevailed in PI patients. Coleman et al suggested that EBV-2 may
establish a prolonged transient infection in the T cells subsequent
to primary infection, that is lost with age (Coleman et al., 2018).
Quite the opposite, our findings indicate that EBV type 1 infection
in PI children is prevalent, suggesting that EBV-2 may appear in
subsequent reinfections at older ages.
This work presents the comparative characteristics of the EBV
infection among PI, HC and R patients in our population, at the site
of viral entry and reactivation. These findings are remarkable in
comparison with those previously described in cohorts from either
developed or developing countries, and may explain, at least in
part, the asymptomatic viral infection in children from an
underdeveloped region, given that the establishment of the viral
persistence may be associated with the low viral inoculum and the
lack of latency antigen expression in early stages of the primary
infection. In addition, our results also challenge the typical LIII
pattern described in patients undergoing primary infection.
Materials & methods
Ethics statement
All samples were collected after written consent (patients older
than 12 years old and legal guardians of children younger than 12
years old) and assent (7to 12 years old patients andlegal guardians of
children older than 12 years old) was obtained; following the
national and international ethics standards and under the supervi-
sion of the Ethical Committee of the Ricardo Gutiérrez Children’s
Hospital, in accordance to the Helsinki Declaration of 1975.
Patients and samples
Formalin fixed paraffin embedded (FFPE), 70 C frozen tonsils
tissue and blood samples were collected from 54 children aged
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due to non-reactive hyperplasia at the Otorhinolaryngology
Division, Ricardo Gutierrez Children’s Hospital (Buenos Aires,
Argentina). Tonsillar hyperplasia was diagnosed according to
international routine protocols for recurrent chronic inflamma-
tion. Tonsils were not acutely swollen at the time of removal.
Serological status
Blood samples were incubated 1 hour at 37 C, and then
centrifuged at 3500 rpm for 5 min. The serum was collected and
frozen at 20 C. Serological status was assessed by the presence of
VCA-IgM, VCA-IgG titration (diluted 1/10, 1/40 and 1/320),
presence of Early Antigen (EA)-IgG and EBNA1-IgG, as previously
described (Klutts et al., 2009).
DNA extraction and viral load
In order to assess EBV viral load specifically at the tonsil
samples, DNA was extracted from fresh tissue samples using
commercial columns (QIAGEN) according to manufacturer’s
instructions. The extraction product was quantified using Nano-
Drop One (Thermo Fisher) and its integrity checked by a PCR assay
for human ẞ-globin. The samples were diluted so a total of 100 ng
of DNA were used in the qPCR assay.
Viral load was assessed through quantitative PCR in the
StepOne (Applied Biosystems) using TaqMan probe (ROX). As
previously described (Fellner et al., 2016), this assay amplifies a
single copy viral gene, EBNA1.
EBV Typing
PCR directed against EBNA3C gene, which exhibits a deletion in
EBV type 1 in comparison with type 2, was performed. This
difference in length generates a PCR product for EBV type 1 shorter
(157 bp) than that observed in EBV type 2 (246 bp). The PCR assay
was performed according to Sample et al. (1990) and, in cases that
could not be typified, we performed a semi nested PCR using in the
first round a reverse primer against a farther region in the EBNA3C
(Rv: 5’-AGCAGTAGCTTGGGAACACC-3’) and, in the second round,
the primers previously described (Sample et al., 1990).
EBERs In-Situ hybridization (ISH) & Immunohistochemistry (IHC)
To determine viral latency, we performed in-situ hybridization
with ViewRNA ISH Tissue 1-Plex Assay and specific probes
(Affymetrix) to detect the presence of EBERs transcripts according
manufacturer protocol. Immunohistochemistry (IHC) was per-
formed to detect and localize EBV latent and lytic protein
expression, using the following antibodies: mouse Anti-LMP1
(Dako), rat Anti-LMP2A (ABCAM), rat Anti-EBNA2 (supernatant, R3
clone, Kremmer) and mouse Anti-BMRF1 (ABCAM), as previously
described (Cohen et al., 2013). The positive controls were
performed in FFPE EBV + cell lines Raji (for EBNA2), P3HR1 treated
with TPA (12-O-tetradecanoylphorbol-13-acetate, Sigma) to stim-
ulate lytic infection (for BMRF1), FFPE EBV positive diffuse large B-
cell lymphoma (for EBERs) and Hodgkin Lymphoma (for LMP1 and
2A) (Figure S1). As negative controls, we performed the same
method without the primary antibody. In all cases, we analyze the
whole section to assess the presence or absence of immunohisto-
chemical staining.
Statistical analysis
The data was analyzed using GraphPad Prism 5 software. Group
normality was tested using Shapiro–Wilks test. Comparisonbetween groups was assessed by 1-way ANOVA or Kruskal–Wallis
test according to the normality test results, and correlations were
tested using Spearman test. Categorical variables were analyzed
with Fisher exact test. Outliers were defined using Robust test to
compare data median absolute deviation (Mad) in Excel. All tests
were two-tailed, and p < 0.05 was considered statistically
significant.
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